21 articles for thisTarget

---

The following articles (labelled with PubMed ID or TBD) are for your review

PMID	Data	Article Title	Organization
27598236	59	High-affinity small molecular blockers of mixed lineage leukemia 1 (MLL1)-WDR5 interaction inhibit MLL1 complex H3K4 methyltransferase activity.	China Pharmaceutical University
27720555	29	Structure-based design of ester compounds to inhibit MLL complex catalytic activity by targeting mixed lineage leukemia 1 (MLL1)-WDR5 interaction.	China Pharmaceutical University
27116709	28	Structure-based design and synthesis of small molecular inhibitors disturbing the interaction of MLL1-WDR5.	China Pharmaceutical University
26958703	19	Structure-Based Optimization of a Small Molecule Antagonist of the Interaction Between WD Repeat-Containing Protein 5 (WDR5) and Mixed-Lineage Leukemia 1 (MLL1).	Ontario Institute For Cancer Research
24900672	41	Synthesis, Optimization, and Evaluation of Novel Small Molecules as Antagonists of WDR5-MLL Interaction.	Entremed
20575550	54	Analysis of the binding of mixed lineage leukemia 1 (MLL1) and histone 3 peptides to WD repeat domain 5 (WDR5) for the design of inhibitors of the MLL1-WDR5 interaction.	University of Michigan
32223236	31	Discovery of WD Repeat-Containing Protein 5 (WDR5)-MYC Inhibitors Using Fragment-Based Methods and Structure-Based Design.	Vanderbilt University
31724864	148	Discovery and Optimization of Salicylic Acid-Derived Sulfonamide Inhibitors of the WD Repeat-Containing Protein 5-MYC Protein-Protein Interaction.	Vanderbilt University
31858797	22	Discovery and Structure-Based Optimization of Potent and Selective WD Repeat Domain 5 (WDR5) Inhibitors Containing a Dihydroisoquinolinone Bicyclic Core.	Frederick National Laboratory For Cancer Research
30626558	28	The identification of novel small-molecule inhibitors targeting WDR5-MLL1 interaction through fluorescence polarization based high-throughput screening.	Zhejiang Sci-Tech University
29889518	68	Discovery of Potent 2-Aryl-6,7-dihydro-5 H-pyrrolo[1,2- a]imidazoles as WDR5-WIN-Site Inhibitors Using Fragment-Based Methods and Structure-Based Design.	TBA
29254892	18	Targeting protein-protein interaction between MLL1 and reciprocal proteins for leukemia therapy.	China Pharmaceutical University
28135235	71	An allosteric PRC2 inhibitor targeting the H3K27me3 binding pocket of EED.	Novartis Institutes For Biomedical Research